FibroGen (NASDAQ:FGEN) Second Quarter 2025 Results

Key Financial Results

• Net loss: US$13.7m (loss narrowed by 71% from 2Q 2024).
• US$3.39 loss per share (improved from US$11.79 loss in 2Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

FibroGen Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 53%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is expected to decline by 3.5% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%.

Performance of the American Biotechs industry.

The company's shares are up 39% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for FibroGen (2 can't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.